# Diphenidine Placement in Schedule I Controlled Substances > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/diphenidine-schedule-i-controlled-substance-update/ > **Published:** 2026-06-21T12:56:20-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:38:17-04:00 > **Clinical Summary:** Learn about diphenidine schedule i controlled substance designation and its implications under the Controlled Substances Act. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesdiphenidine_schedule_Istate_regulationmarijuana_legislation Clinical Summary The DEA has placed diphenidine, a synthetic dissociative drug, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act, designating it as having no accepted medical use and high abuse potential. Diphenidine is a structural analog of phenibut and other dissociatives that has emerged in illicit drug markets as a substitute for regulated dissociatives like ketamine and phencyclidine. This scheduling action reflects the government’s response to novel psychoactive substances that bypass existing regulations by chemically modifying known drugs of abuse. While diphenidine itself has no established clinical applications in cannabis or general medical practice, the regulatory mechanism demonstrated here is relevant to clinicians as it illustrates how synthetic drug analogs rapidly enter unregulated markets and how scheduling responds to emerging [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) threats. Clinicians should be aware that patients presenting with acute intoxication or dependence related to novel dissociative compounds may have limited treatment protocols available compared to established drugs. The practical takeaway is that clinicians encountering patients with exposure to novel synthetic drugs should maintain awareness of emerging scheduling actions and consult poison control or addiction specialists for management guidance, as these compounds often lack established safety data and treatment protocols. Clinical Perspective 🧠 The DEA’s placement of diphenidine in Schedule I reflects growing concern about novel synthetic drugs that circumvent existing regulations, though this particular substance has limited documented clinical presence in the United States. Diphenidine is a dissociative compound structurally similar to other controlled dissociatives and has been primarily identified in illicit drug markets overseas, making its practical relevance to most clinical practices in the US fairly limited at this time. Healthcare providers should be aware that Schedule I designation may reduce future research opportunities into whether this or similar dissociatives might have therapeutic applications, though the [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) risk from uncontrolled availability appears to have driven the regulatory decision. Clinically, this serves as a reminder to maintain vigilance for novel synthetic dissociatives presenting as adulterants in street drugs or as emerging substances of abuse, particularly among patients with dissociative or depersonalization symptoms or those presenting with unexplained acute psychiatric or neurological 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Diphenidine+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Diphenidine+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/cumyl-pegaclone-schedule-i-placement-dea-synthetic-cannabinoid/) - Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Temporary Placement of 2-Fluorodeschloroketamine in Schedule I - [Policy Watch: 20 Regulatory Updates — June 19, 2026](https://cedclinic.com/dea-schedule-i-synthetic-cannabinoids-control-update-june-2026/) 📰 Source: [https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i](https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of Diphenidine in Schedule I](https://cedclinic.com/diphenidine-regulatory-scheduling-update-schedule-i/) Explore detailed regulatory updates on diphenidine’s placement in Schedule I and its implications. [Read More](https://cedclinic.com/diphenidine-regulatory-scheduling-update-schedule-i/) [Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) Review the temporary scheduling of 2-Fluorodeschloroketamine as a comparison to diphenidine’s regulatory status. [Learn More](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) [Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/cumyl-pegaclone-schedule-i-placement-dea-synthetic-cannabinoid/) Understand the scheduling process through the example of CUMYL-PEGACLONE’s placement in Schedule I. [Explore](https://cedclinic.com/cumyl-pegaclone-schedule-i-placement-dea-synthetic-cannabinoid/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).